Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Light-Activated Nanoparticles Kill Primary Tumors and Distant Metastases

By LabMedica International staff writers
Posted on 27 Sep 2016
A novel type of nanoparticle carries two anticancer drugs to attack colorectal cancer while simultaneously recruiting and activating T-cells to fight the tumors.

Advanced colorectal cancer is one of the deadliest cancers, with a five-year survival rate of only 12% for patients with the metastatic disease. More...
Checkpoint blockade therapy, which counters biochemical signals transmitted by the cancer cells to suppress the immune system and prevent recognition by T-cells, is among the most promising immunotherapies for patients with advanced colon cancer, but has not been particularly successful. This is due in part to the lack of T-cells inside well-established tumors and the difficulty in attracting T-cells from other parts of the body to the tumor.

Investigators at the University of Chicago (IL, USA) have developed a method to enhance the effectiveness of checkpoint blockade therapy. They developed a novel type of nanoparticle assembled from zinc and the drug oxaliplatin, an agent in regular use against advanced-stage metastatic colon cancer. The photosensitizing agent pyrolipid, which attacks tumors following light activation, was used to coat the outer layer of the particles. The nanoparticles therefore represented a method for the effective delivery of both chemotherapy and photodynamic therapy (PDT).

The effectiveness of the particles when tested in a mouse model was as evidenced by early calreticulin (CRT) exposure on the cell surface, antitumor vaccination, tumor-specific T-cell response, and an abscopal effect. The abscopal effect is usually described with ionizing radiation and refers to regression of a tumor outside of the irradiated volume. Although the mechanism is unknown, it is thought to be immune modulated.

The investigators reported in the August 17, 2016, online edition of the journal Nature Communications that in a mouse model nanoparticle treatment in combination with PD-L1 checkpoint blockade, therapy not only led to the regression of the primary tumors treated locally with light irradiation, but also mediated regression of non-irradiated distant tumors by inducing a strong tumor-specific immune response.

“Everybody out there working in the cancer space is trying to figure out ways to enhance checkpoint blockade immunotherapy,” said senior author Dr. Wenbin Lin, professor of chemistry at the University of Chicago. “In this work, we were able to achieve that. We believe that this combination is able to activate the immune system to generate the T-cells that will recognize the cancer cells. Then they go around the body and kill the cancer cells in the distant site that has not been irradiated with the light.”

Related Links:
University of Chicago


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.